CD200 (Cluster of Differentiation 200) is a widely expressed membrane glycoprotein that serves as a critical immune checkpoint molecule in the central nervous system. Originally identified as an immunoregulatory protein, CD200 interacts with its receptor CD200R to deliver inhibitory signals that suppress myeloid cell activation, including microglial cells in the brain. This signaling axis represents one of the most important mechanisms maintaining neuroimmune homeostasis[1][2].
| CD200 - Immune Checkpoint Glycoprotein | |
|---|---|
| Gene Symbol | CD200 |
| Full Name | CD200 Molecule (OX-2 Membrane Glycoprotein) |
| Chromosome | 3q12-q13 |
| NCBI Gene ID | [1745](https://www.ncbi.nlm.nih.gov/gene/1745) |
| OMIM | 155730 |
| Ensembl ID | ENSG00000100288 |
| UniProt ID | [P14210](https://www.uniprot.org/uniprot/P14210) |
| Protein Class | Immunoglobulin Superfamily / Immune Checkpoint |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Multiple Sclerosis, Stroke, Brain Aging |
The CD200 gene spans approximately 6.5 kb on chromosome 3q12-13 and consists of 5 exons encoding a 269 amino acid type I membrane glycoprotein. The gene structure is conserved across mammals, reflecting the fundamental importance of this immune regulatory pathway.
The CD200 protein contains several distinct structural features[3]:
| Feature | Details | Function |
|---|---|---|
| N-terminal Ig-like domain | 1-120 | Ligand binding, receptor interaction |
| MHC-like domain | 120-200 | Structural stability |
| Proline-rich region | 200-230 | Flexibility |
| Transmembrane domain | 230-250 | Membrane anchoring |
| Cytoplasmic tail | 250-269 | Signaling (minimal) |
As a type I membrane protein, CD200 presents its extracellular Ig-like domain for interaction with CD200R on neighboring cells. The cytoplasmic tail is remarkably short, suggesting that CD200 functions primarily as a ligand rather than a signaling molecule itself.
CD200 is broadly expressed in the central nervous system:
| Cell Type | Expression Level | Notes |
|---|---|---|
| Neurons | High | Particularly in cortex, hippocampus |
| Astrocytes | Moderate | Variable by region and state |
| Oligodendrocytes | Moderate | Higher in mature cells |
| Endothelial cells | High | Blood-brain barrier expression |
| Microglia | Low | Minimal expression under normal conditions |
CD200R (CD200 Receptor) is expressed predominantly on myeloid cells:
Upon CD200-CD200R interaction, the following sequence occurs[4][3:1]:
This mechanism provides a constitutive "off signal" that keeps microglia in a quiescent state under normal conditions.
The CD200-CD200R axis shares conceptual similarities with other immune checkpoint pathways:
| Checkpoint | Ligand | Receptor | Primary Function |
|---|---|---|---|
| CD200-CD200R | CD200 | CD200R | Inhibits myeloid cell activation |
| PD-1/PD-L1 | PD-L1 | PD-1 | T cell exhaustion |
| CTLA-4/CD80 | CD80 | CTLA-4 | T cell co-stimulation blockade |
However, CD200-CD200R is unique in its constitutive expression and role in CNS immune homeostasis.
Under physiological conditions, CD200-CD200R signaling maintains microglia in a resting state characterized by[5][2:1]:
This "surveilling" state allows microglia to perform essential functions like synaptic pruning and debris clearance without triggering destructive inflammation.
In neurodegenerative diseases, the CD200-CD200R axis is disrupted through multiple mechanisms[6]:
Reduced CD200 Expression:
CD200R Alterations:
Functional Consequences:
CD200 dysfunction contributes to AD pathogenesis through multiple mechanisms[7][8]:
Amyloid Effects:
Synaptic Impairment:
Therapeutic Potential:
In PD, the CD200-CD200R pathway is implicated in dopaminergic neuron survival[9]:
Substantia Nigra Vulnerability:
Neuroprotection:
CD200 signaling is altered in MS and related demyelinating diseases[10]:
Lesion Environment:
Therapeutic Implications:
Following ischemic injury, CD200 plays complex roles[11]:
Acute Phase:
Chronic Phase:
Potential for Intervention:
CD200 expression naturally declines with aging[12]:
CD200 interacts with multiple proteins and pathways:
| Partner | Interaction Type | Functional Significance |
|---|---|---|
| CD200R | Direct binding | Primary signaling receptor |
| CD200R1 | Alternative receptor | Similar inhibitory function |
| SHP-1 | Downstream signaling | Phosphatase recruitment |
| SHP-2 | Downstream signaling | Phosphatase recruitment |
| Aβ oligomers | Pathological interaction | Reduces CD200 expression |
| NFTs | Pathological association | Tau pathology impact |
Multiple therapeutic strategies are being explored[6:1]:
Agonist Development:
Gene Therapy:
Combination Approaches:
Characterization of the CD200 receptor family. Immunogenetics. 2000. ↩︎
CD200-CD200R immune checkpoint in brain aging and neurodegeneration. Nat Rev Neurosci. 2020. ↩︎ ↩︎
CD200 receptor trafficking and signaling. J Immunol. 2011. ↩︎ ↩︎
CD200 and its receptor, CD200R. Immunol Rev. 2000. ↩︎
CD200-CD200R pathway in the regulation of brain immune homeostasis. Neurosci Bull. 2011. ↩︎
Targeting CD200-CD200R in neuroinflammation. Trends Immunol. 2019. ↩︎ ↩︎
Microglial activation states and the CD200 pathway in AD. Brain. 2021. ↩︎
CD200 dysfunction in neuron contributes to synaptic deficits and cognitive decline. J Neurosci. 2020. ↩︎
CD200 in Parkinson's disease and neuroprotection. Neurobiol Aging. 2019. ↩︎
CD200 deficiency in multiple sclerosis. Ann Neurol. 2017. ↩︎
CD200 and neuroinflammation after stroke. J Cereb Blood Flow Metab. 2019. ↩︎
CD200 expression changes in aging brain. Neurobiol Aging. 2018. ↩︎